Switch to biosimilars: what we’ve got in Asia and what is the situation in the West?

Kaichun Wu   

*Genetic predictors for primary and secondary loss of response to TNF in CD

Yoichi Kakuta   

Defining the path forward for biomarkers to address unmet TDM needs

Yao He   

*When should switch to second biologics for Crohn’s disease?

Ida Hilmi   

*Biologics & Small Molecules in IBD for Asia Setting: Which one and how to monitor?

Siew C Ng   

The algorithms for accelerated treatment of acute severe ulcerative colitis- experience and suggestion

Laurent Peyrin-Biroulet   

Coffee Break